ConductScience.org, home

Paper36795409

Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer.

Cella CA and 15 others. JAMA Netw Open, 2023. Cited by 20 papers, by iCite.

Cite this record

ConductScience Library. Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer. Papers, record 36795409. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36795409

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer.
PubMed
Journal
JAMA Netw Open
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
2.88
iCite
Revised in PubMed
2023-02-22
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cella CAChiara A
2Knoedler MMaren
3Hall MMarcia
4Arcopinto MMichele
5Bagnardi VVincenzo
6Gervaso LLorenzo
7Pellicori SStefania
8Spada FFrancesca
9Zampino MGMaria G
10Ravenda PSPaola S
11Frassoni SSamuele
12Passaro AAntonio
13Milano MMonica
14Laffi AAlice
15Fazio NNicola
16Lordick FFlorian

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Venous ThromboembolismMajor topic
NeoplasmsMajor topic
Humans
Female
Middle Aged
Outpatients
Prospective Studies
Risk Assessment

Source PubMed

Download CSV of topics

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127882374Cancer-associated venous thromboembolism: Burden, mechanisms, and management.Thromb Haemost2017https://conductscience.org/library/papers/27882374PubMed
234396323Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review.JACC CardioOncol2021https://conductscience.org/library/papers/34396323PubMed
320097409Venous thromboembolism and prognosis in cancer.Thromb Res2010https://conductscience.org/library/papers/20097409PubMed
4314926322019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.Lancet Oncol2019https://conductscience.org/library/papers/31492632PubMed
526114207Guideline on aspects of cancer-related venous thrombosis.Br J Haematol2015https://conductscience.org/library/papers/26114207PubMed
631353841The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH.J Thromb Haemost2019https://conductscience.org/library/papers/31353841PubMed
724141714World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.JAMA2013https://conductscience.org/library/papers/24141714PubMed
830919253Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients.J Thromb Thrombolysis2019https://conductscience.org/library/papers/30919253PubMed
929885940A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts.Lancet Haematol2018https://conductscience.org/library/papers/29885940PubMed
1028550192Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study.Haematologica2017https://conductscience.org/library/papers/28550192PubMed
1122547369A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score.Intern Emerg Med2012https://conductscience.org/library/papers/22547369PubMed
1232580190Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients.Oncol Res Treat2020https://conductscience.org/library/papers/32580190PubMed
1319726226
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.
Lancet Oncol2009https://conductscience.org/library/papers/19726226PubMed
1420829374Prediction of venous thromboembolism in cancer patients.Blood2010https://conductscience.org/library/papers/20829374PubMed
1521908511Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines.Ann Oncol2011https://conductscience.org/library/papers/21908511PubMed
1618216292Development and validation of a predictive model for chemotherapy-associated thrombosis.Blood2008https://conductscience.org/library/papers/18216292PubMed
1731381464Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.J Clin Oncol2020https://conductscience.org/library/papers/31381464PubMed
1833570602American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.Blood Adv2021https://conductscience.org/library/papers/33570602PubMed
1925987694Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial.J Clin Oncol2015https://conductscience.org/library/papers/25987694PubMed
2030511879Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.N Engl J Med2019https://conductscience.org/library/papers/30511879PubMed

See all 29 referencesDownload CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
42555406Enhancing venous thromboembolism risk prediction after immunotherapy for lung cancer.iScience2026https://conductscience.org/library/papers/42555406PubMed
42163826Emerging Insights of Management of Venous Thromboembolism in Patients With Cancer.Clin Appl Thromb Hemost2026https://conductscience.org/library/papers/42163826PubMed
41847697Thromboembolic disease in testicular germ cell tumors-real-world evidence of three Portuguese institutions.Front Oncol2026https://conductscience.org/library/papers/41847697PubMed
41228199The Clinical Utility of Selected Coagulation Parameters in Predicting the Risk of Venous Thromboembolism in Neuroendocrine Tumours: A Prospective, Single-Centre Study.Cancers (Basel)2025https://conductscience.org/library/papers/41228199PubMed
41154365Comparative Evaluation of Risk Assessment Models for Predicting Venous Thromboembolic Events in Cancer Patients with Implanted Central Venous Access Devices.Cancers (Basel)2025https://conductscience.org/library/papers/41154365PubMed
40325237Venous thromboembolic risk in hematological hospitalized patients: a retrospective study.Ann Hematol2025https://conductscience.org/library/papers/40325237PubMed
40291141Development, validation, and clinical utility of risk prediction models for cancer-associated venous thromboembolism: A retrospective and prospective cohort study.Asia Pac J Oncol Nurs2025https://conductscience.org/library/papers/40291141PubMed
39110395SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023).Clin Transl Oncol2024https://conductscience.org/library/papers/39110395PubMed
38730721Gynecological Cancer and Venous Thromboembolism: A Narrative Review to Increase Awareness and Improve Risk Assessment and Prevention.Cancers (Basel)2024https://conductscience.org/library/papers/38730721PubMed
38625997Decision theoretical foundations of clinical practice guidelines: an extension of the ASH thrombophilia guidelines.Blood Adv2024https://conductscience.org/library/papers/38625997PubMed
38617046Venous thromboembolism in pancreatic neuroendocrine neoplasm: a cohort study.Res Pract Thromb Haemost2024https://conductscience.org/library/papers/38617046PubMed
38275899Novel Insights in Venous Thromboembolism Risk Assessment Methods in Ambulatory Cancer Patients: From the Guidelines to Clinical Practice.Cancers (Basel)2024https://conductscience.org/library/papers/38275899PubMed
37227679Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive.Intern Emerg Med2023https://conductscience.org/library/papers/37227679PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
SELP6403PubTator's text mininghttps://conductscience.org/library/genes/6403

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36795409

GET https://conductscience.org/api/papers/v1/36795409/references?page=2